Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe right time to start Mounjaro is when a qualified prescriber has assessed your medical history, confirmed you meet the licensed eligibility criteria, and weighed up any conditions that might affect how you respond to treatment. There is no universal calendar date — readiness is clinical, not seasonal. Mounjaro (tirzepatide) is a prescription-only medicine licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition. A prescriber, not a checklist, makes the final call.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The licensed eligibility threshold is straightforward on paper: a BMI of 30 or above, or 27 or above if you have at least one weight-related condition. In practice, though, BMI is the starting point of a conversation, not the end of it. A prescriber will consider your full clinical picture (blood pressure, metabolic health, any history of pancreatitis or thyroid conditions, current medications) before deciding whether Mounjaro is appropriate for you right now.
Lower BMI thresholds apply under UK guidance for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, where a 2.5 kg/m² reduction is recommended. You can check your own BMI using the NHS BMI calculator before your consultation, which gives you a useful reference point. If you want to understand the wider licensed criteria in more detail, the Mounjaro overview page on the nume site covers them alongside everything else you'd want to know about the medicine.
One thing worth saying plainly: meeting the BMI threshold is necessary but not sufficient. Eligibility rules out certain people (those who are pregnant, trying to conceive, breastfeeding, or under 18, for instance) and a prescriber will screen for contraindications that an online eligibility checker simply cannot catch. That clinical review is the bit that makes a prescription legitimate.
This is the question our prescribers hear most weeks, and the honest answer depends entirely on your circumstances. NHS access to Mounjaro under NICE's tirzepatide appraisal is being phased in gradually, the first cohort, for people with a BMI of 40 or above and four or more qualifying conditions, became available from June 2025. A second cohort covering BMI 35–39.9 with four or more conditions was activated in June 2026. NICE's technology appraisal TA1026 sets out the full phased timeline if you want the specifics.
If you fall outside those cohorts, or simply do not want to wait, a private route through a GPhC-registered pharmacy is the legal alternative, provided a prescriber assesses you and issues a prescription. There is no shortcut around that step. For a plain comparison of costs in the private market, the Mounjaro cost page gives an honest picture of what private treatment involves financially. Thinking through the NHS versus private question carefully before you start saves you from switching mid-treatment, which can disrupt your titration schedule.
If you are in Scotland, Wales or Northern Ireland, eligibility criteria differ from England's, access thresholds and support requirements are set by the devolved health services. Keep that in mind when reading England-specific NHS guidance.
Mounjaro works best alongside real lifestyle change, a consistently lower-calorie diet and regular movement. Starting during a period of sustained disruption (a house move, an imminent long-haul trip, major surgery on the horizon) is not automatically disqualifying, but it is worth discussing with your prescriber. Surgery deserves particular mention: you should tell your anaesthetist and surgical team that you are taking a GLP-1 medicine before any procedure, because gastric emptying is slowed and this carries anaesthetic implications. NHS England's guidance on weight management injections covers the surgery consideration and the contraception advice below.
Contraception is another practical timing factor. Women taking oral contraceptives should use an additional non-oral method (condoms, for example) for the first four weeks of Mounjaro treatment and for four weeks after each dose increase, because absorption of the pill may be reduced. If you use HRT, it is worth discussing whether a transdermal format (a patch or gel rather than a tablet) makes sense while you are on tirzepatide. These are conversations to have before day one, not after. A fuller look at the practical steps around beginning treatment is on the how to start Mounjaro page.
The question of when you will first notice something changing is separate from when the medicine is actually working. How quickly Mounjaro takes effect depends on individual physiology, and most people notice appetite shifts before the scales move.
The first pen contains four 2.5 mg doses, one injection per week for four weeks. The 2.5 mg level exists to let your digestive system adapt; it is not the dose at which most people see significant weight change. Nausea is common at each step up, particularly in the first few days after a new dose, and usually settles. Eating smaller portions, avoiding very fatty meals and staying well hydrated all help. You will not need to handle a clinical schedule yourself: your prescriber adjusts the dose, and our frequently asked questions page covers the kinds of practical queries that come up most.
When your treatment is approved through nume, it is dispatched the same day (for orders confirmed before 12pm, Monday to Friday) and delivered the next working day by DPD. The tracking notification arrives on your phone; the box itself is plain, with no branding visible from outside. Inside you will find the KwikPen, which requires refrigeration until first use. That is a practical detail worth planning for before your first delivery lands.
Results over the longer term are meaningful. In the SURMOUNT-1 trial (2,539 adults with obesity over 72 weeks) participants on the 15 mg maintenance dose lost an average of around 20–21% of their body weight. When weight loss typically begins is a common follow-up question, and the answer involves more nuance than a single week number. The clinical evidence underlying these figures comes from the SURMOUNT trials; the tirzepatide science page goes deeper on the mechanism if you want it.
If you are ready to talk through your own situation, our prescribers can review your consultation the same day. Start your free consultation and a GPhC-registered Independent Prescriber will assess whether now is the right time for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.